JP2022183342A5 - - Google Patents

Download PDF

Info

Publication number
JP2022183342A5
JP2022183342A5 JP2022168742A JP2022168742A JP2022183342A5 JP 2022183342 A5 JP2022183342 A5 JP 2022183342A5 JP 2022168742 A JP2022168742 A JP 2022168742A JP 2022168742 A JP2022168742 A JP 2022168742A JP 2022183342 A5 JP2022183342 A5 JP 2022183342A5
Authority
JP
Japan
Prior art keywords
tumor
pharmaceutical composition
medicament
group
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022168742A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022183342A (ja
Filing date
Publication date
Priority claimed from JP2020129898A external-priority patent/JP2020183447A/ja
Application filed filed Critical
Publication of JP2022183342A publication Critical patent/JP2022183342A/ja
Publication of JP2022183342A5 publication Critical patent/JP2022183342A5/ja
Pending legal-status Critical Current

Links

JP2022168742A 2015-10-15 2022-10-21 併用療法 Pending JP2022183342A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562242123P 2015-10-15 2015-10-15
US62/242,123 2015-10-15
US201662361725P 2016-07-13 2016-07-13
US62/361,725 2016-07-13
JP2020129898A JP2020183447A (ja) 2015-10-15 2020-07-31 併用療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020129898A Division JP2020183447A (ja) 2015-10-15 2020-07-31 併用療法

Publications (2)

Publication Number Publication Date
JP2022183342A JP2022183342A (ja) 2022-12-08
JP2022183342A5 true JP2022183342A5 (https=) 2022-12-21

Family

ID=58518110

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018519304A Active JP6850290B2 (ja) 2015-10-15 2016-10-14 併用療法
JP2020129898A Withdrawn JP2020183447A (ja) 2015-10-15 2020-07-31 併用療法
JP2022168742A Pending JP2022183342A (ja) 2015-10-15 2022-10-21 併用療法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018519304A Active JP6850290B2 (ja) 2015-10-15 2016-10-14 併用療法
JP2020129898A Withdrawn JP2020183447A (ja) 2015-10-15 2020-07-31 併用療法

Country Status (5)

Country Link
US (3) US10744170B2 (https=)
EP (1) EP3362091A4 (https=)
JP (3) JP6850290B2 (https=)
CN (1) CN108697788A (https=)
WO (1) WO2017066557A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
WO2018067446A1 (en) 2016-10-06 2018-04-12 Duke University Detection of cd-155, the poliovirus receptor
EP3525822A4 (en) 2016-10-17 2020-05-06 Duke University PRODUCTION OF IMMUNOTOXIN D2C7- (SCDSFV) -PE38KDEL
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP7550449B2 (ja) * 2018-04-02 2024-09-13 デューク ユニバーシティ ネオアジュバントがん治療
EP4051321A4 (en) 2019-10-30 2023-11-22 Duke University IMMUNOTHERAPY WITH COMBINATION THERAPY INCLUDING AN IMMUNOTOXIN
US20220387529A1 (en) * 2019-11-04 2022-12-08 Duke University Treatment for primary and metastatic cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8066983B2 (en) 2008-03-14 2011-11-29 The Research Foundation Of State University Of New York Attenuated poliovirus
WO2013112942A1 (en) * 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
CN104936608A (zh) * 2012-11-21 2015-09-23 杜克大学 用于人肿瘤的溶瘤脊髓灰质炎病毒
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
US10835595B2 (en) * 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2022183342A5 (https=)
JP2020183447A5 (https=)
Ali et al. Sleep, immunity and inflammation in gastrointestinal disorders
EP4509527A3 (en) Post-translationally modified fully human antibody therapeutic agents
Natah et al. Effects of acute hypoxia and hyperthermia on the permeability of the blood-brain barrier in adult rats
Leslie et al. Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis
JP2017506662A5 (https=)
JP2016199571A (ja) 組み合わせ医薬組成物並びに回転性めまい、動揺病及び自律神経血管ジストニアを治療する方法
JP2021520368A5 (https=)
Pellegrini et al. Therapeutic benefit of a combined strategy using erythropoietin and endothelial progenitor cells after transient focal cerebral ischemia in rats
JP2012522788A5 (https=)
US8703124B2 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
JP2018508208A5 (https=)
James et al. How murine models of human disease and immunity are influenced by housing temperature and mild thermal stress
Yuan et al. Screening for protective antigens of Cyprinid herpesvirus 2 and construction of DNA vaccines
JP5688699B2 (ja) がん細胞を用いた免疫方法
Romero Enteroviruses
Zhao et al. Protective immunity against infectious spleen and kidney necrosis virus induced by mannose modified subunit vaccine with carbon nanotubes in mandarin fish
Jiang et al. The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVΔ51 via aggravating endoplasmic reticulum stress
WO2024193321A1 (zh) Glyt1抑制剂在治疗器官纤维化中的应用
EP1383872A2 (de) Genmodifizierte yt zelllinie und ihre verwendung
CN117264904A (zh) 一种靶向HER2的γδT细胞及其制备方法与应用
CN115109161A (zh) 含有间充质干细胞的减肥药物组合物
Kleinovink et al. Combination of Photodynamic Therapy and Immune Checkpoint Blockade
Soliman et al. Development and production of Rabies virus-specific monoclonal antibodies and evaluation of their neutralizing and protective potentials